November 6, 2009 – Cardiac support device maker Abiomed Inc. yesterday announced second quarter fiscal 2010 revenue of $20 million.
U.S. commercial Impella revenue totaled $12.1 million, up 95 percent compared to revenue of $6.2 million in the second quarter of fiscal 2009. U.S. commercial reorders totaled $6.6 million, up 230 percent from $2 million in the second quarter of fiscal 2009.
Worldwide Impella revenue was $13.2 million, up 26 percent compared to revenue of $10.5 million for the second quarter of fiscal 2009.
The company said about 338 U.S. commercial patients were treated with Impella 2.5, 5.0 or LD, a 238 increase compared to approximately 100 patients in the second quarter of fiscal 2009. More than 1,200 U.S. commercial patients have been treated with Impella as of the end of the second quarter of fiscal 2010.
An additional 50 U.S. hospitals purchased Impella 2.5 for commercial use during the quarter, bringing the total to 326 commercial customers, Abiomed said.
During the second quarter of fiscal 2010, there were 28 patients enrolled in the Protect II study, for a total of 290 patients completed, or 44 percent of the 654 patients required.
Legacy revenue, which consists of non-Impella revenue, was $6.8 million or 28 percent lower than the second quarter of fiscal 2009.
At TCT in September 2009, Abiomed announced the clinical data from USpella, the first U.S. multicenter registry of 181 Impella 2.5 patients, demonstrating that Impella 2.5 is able to treat patients in the cath lab who were turned down by surgery and decrease their SYNTAX score. high-risk PCI and AMI patients treated with Impella 2.5 showed an improvement in ejection fraction.
Also at TCT 2009, data released from the Academic Medical Center MACH II three-year follow-up results revealed that patients in the Impella 2.5 arm of the trial showed improved left ventricular function, cardiac output and quality of life.
For more information: www.abiomed.com